Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemotherapy at home for leukemia: a feasibility test

NCT ID NCT07802015

Knowledge-focused Sponsor: Zealand University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This study explores whether patients with acute myeloid leukemia can receive intravenous cytarabine chemotherapy at home instead of in the hospital. Researchers will track how many patients complete the planned home treatment, how often doses are given at home versus the hospital, and any safety issues. They will also measure costs, quality of life, and the experiences of patients, caregivers, and healthcare professionals. The goal is to understand if home-based chemotherapy is a practical and safe option in Denmark.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intravenous cytarabine administered at home
What this could lead to
If home-based cytarabine proves feasible and safe, it could allow more AML patients to receive chemotherapy at home, reducing hospital stays and improving quality of life.
What could go wrong
This is an observational feasibility study, not a randomized trial, so it cannot prove whether home treatment is as effective as hospital care. Safety risks include infections or complications that may require urgent hospital transfer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study 2: Participants diagnosed with AML, aged ≥ 18 years, who are to receive treatment with IV-Cytarabine and their appointed primary caregiver, who can provide informed consent are eligible for inclusion. A primary caregiver is a individual providing frequent support and attending to the physical and emotional needs of someone requiring ongoing assistance. Inability to read, write and/or speak Danish or English, or deemed unethical to participate due to mental disability, are ineligible for inclusion in the study. Patients and their primary caregiver, identified by patients, will be recruited from all Danish hematologic departments offering home-based IV-Cytarabine treatment: Aarhus University Hospital, Aalborg University Hospital, Copenhagen University Hospital, Odense University Hospital, and Zealand University Hospital.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: PATIENT (Study 2+3) * Age ≥ 18 years * Can provide informed consent. * Participants that have been diagnosed with AML, to receive IV-Cytarabine CAREGIVER (Study 2+3) * Age ≥18 years * Can provide informed consent. HEALTHCARE PROFESSIONALS (Study 3) * Employed as Physician or Registered Nurse * Work experience with home-based treatment for patients with AML for minimum 1 year. Exclusion Criteria (Patient/Caregiver): * Inability to read, write and/or speak Danish or English * Otherwise deemed unethical to participate due to mental disability

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukaemia (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukaemia (AML) Hematologic cancer Home-based chemotherapy Hospital at home

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.